0001641172-25-009724 | 10-Q | XBRL Viewer

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Computation of Basic and Diluted Loss Per Common Share


	For the Three Months Ended
	March 31,
	2025			2024
Numerator:
Net loss attributable to common stockholders	$	(2,256,930	)	$	(2,826,737	)

Denominator (weighted average quantities):
Common shares outstanding		2,545,524			623,600
Add: Prefunded warrants		561,404			-
Denominator for basic and diluted net loss per share		3,106,928			623,600

Basic and Diluted Net Loss per Common Share	$	(0.73	)	$	(4.53	)

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Three Months Ended
	March 31,
	2025		2024
Warrants ^[1] 1		3,852,258		689,520
Options		9,603		10,243
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		3,864,000		701,902

As per of the InflamaCORE, LLC licence agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 6- Commitments and Contingencies -License Agreements for details.

Commitments and Contingencies	3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Litigations, Claims and Assessments The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. *Disputed Vendor Invoices* On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice included miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing the interest and unsupported charges and has requested the vendor to rescind each of them. Although the Company has requested the vendor to rescind the retroactive interest on invoices, the Company believes that in accordance with the agreement, the vendor can legally charge the Company interest from the point they were notified of the vendor’s intent to charge interest. As such, the Company included the calculated interest from July 1, 2024 to March 31, 2025 of $388,450 within accrued expenses and other current liabilities on the condensed consolidated balance sheet at March 31, 2025. The vendor also updated certain interest calculations such that, at March 31, 2025, the vendors interest claim that has not been accrued by the Company is $941,074. *License Agreements* L&F Research LLC The Company entered into a License Agreement with L&F Research LLC (“L&F”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). Waiver A was contingent upon (i) forgiveness by the Company of $351,579 in aggregate principal amount outstanding under a certain convertible note, and (ii) a cash payment by the Company to L&F in the amount of $648,421, on or before March 31, 2023. Waiver B was contingent upon a cash payment by the Company to L&F in the amount of $500,000 on or before the earlier of (x) January 31, 2024, and (y) ten business days from the date that the Company received net proceeds of at least $30,000,000 from the issuance of new equity capital. All other terms of the L&F License Agreement remain in effect. On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A, which also had the effect of canceling the Note Receivable and the Put Option and resulted in a reclassification of 188 shares of common stock and $331,331 classified as temporary equity to permanent equity. On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B. *Operating Leases* On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitment of approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months. The Company recognized rent expense in connection with its operating lease for the three months ended March 31, 2025 and 2024 of $44,196 and $22,047, respectively.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 6 – Commitments and Contingencies

Litigations, Claims and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

Disputed Vendor Invoices

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice included miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing the interest and unsupported charges and has requested the vendor to rescind each of them. Although the Company has requested the vendor to rescind the retroactive interest on invoices, the Company believes that in accordance with the agreement, the vendor can legally charge the Company interest from the point they were notified of the vendor’s intent to charge interest. As such, the Company included the calculated interest from July 1, 2024 to March 31, 2025 of $388,450 within accrued expenses and other current liabilities on the condensed consolidated balance sheet at March 31, 2025. The vendor also updated certain interest calculations such that, at March 31, 2025, the vendors interest claim that has not been accrued by the Company is $941,074.

License Agreements

L&F Research LLC

The Company entered into a License Agreement with L&F Research LLC (“L&F”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). Waiver A was contingent upon (i) forgiveness by the Company of $351,579 in aggregate principal amount outstanding under a certain convertible note, and (ii) a cash payment by the Company to L&F in the amount of $648,421, on or before March 31, 2023. Waiver B was contingent upon a cash payment by the Company to L&F in the amount of $500,000 on or before the earlier of (x) January 31, 2024, and (y) ten business days from the date that the Company received net proceeds of at least $30,000,000 from the issuance of new equity capital. All other terms of the L&F License Agreement remain in effect.

On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A, which also had the effect of canceling the Note Receivable and the Put Option and resulted in a reclassification of 188 shares of common stock and $331,331 classified as temporary equity to permanent equity.

On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B.

Operating Leases

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitment of approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months.

The Company recognized rent expense in connection with its operating lease for the three months ended March 31, 2025 and 2024 of $44,196 and $22,047, respectively.

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of March 31, 2025 and December 31, 2024:

	March 31,		December 31,
	2025		2024

Payroll accrual	$	1,101,584	$	1,039,338
Bonus accrual		726,938		536,500
Interest accrual		388,450		268,972
Other accrued expenses		111,831		41,970
Accrued issuable equity		62,900		-
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,398,964	$	1,894,041

Schedule of Issuance Date Fair Value of Stock Warrants (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2025 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of common stock on date of grant	$ 0.98
Risk free interest rate	4.09%
Expected term (years)	5 years 3 months 18 days
Expected volatility	125.00%
Expected dividends	0.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares	Mar. 31, 2025	Mar. 31, 2024
Inflamacore, LlC License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase common shares	342	342

Going Concern and Management’s Plans	3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 - Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. As of March 31, 2025, the Company had cash of approximately $1.6 million and a working capital deficit of approximately $9.9 million. During the three months ended March 31, 2025, the Company incurred a net loss of approximately $2.3 million and used cash in operations of approximately $1.8 million. The Company has an accumulated deficit of approximately $114.9 million as of March 31, 2025. The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Going Concern and Management’s Plans

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern and Management’s Plans

Note 2 - Going Concern and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

As of March 31, 2025, the Company had cash of approximately $1.6 million and a working capital deficit of approximately $9.9 million. During the three months ended March 31, 2025, the Company incurred a net loss of approximately $2.3 million and used cash in operations of approximately $1.8 million. The Company has an accumulated deficit of approximately $114.9 million as of March 31, 2025.

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Summary of Warrant Activity (Details)

3 Months Ended

Mar. 31, 2025

USD ($)

$ / shares

Equity [Abstract]

Number of warrants, outstanding beginning balance | shares

1,747,093

Weighted average exercise price, beginning balance | $ / shares

$ 59.59

Number of warrants, Issued | shares

2,105,265

^[1]

Weighted average exercise price, Issued | $ / shares

$ 1.00

^[1]

Number of warrants, repriced - old | shares

(957,200)

^[2]

Weighted average exercise price, repriced - old | $ / shares

$ 2.06

^[2]

Number of warrants, repriced - new | shares

957,200

^[2]

Weighted average exercise price, repriced - new | $ / shares

$ 1.00

^[2]

Number of warrants, forfeited | shares

Weighted average exercise price, forfeited | $ / shares

Number of warrants, exercised | shares

Weighted average exercise price, exercised | $ / shares

Number of warrants, outstanding ending balance | shares

3,852,258

^[1]

Weighted average exercise price, ending balance | $ / shares

$ 27.26

^[1]

Weighted average remaining life in years, outstanding

5 years 21 days

^[1]

Aggregate intrinsic value, ending balance | $

^[1]

Number of warrants, exercisable ending balance | shares

1,746,793

^[1]

Weighted average exercise price, Exercisable | $ / shares

$ 58.71

^[1]

Weighted average remaining life in years, exercisable

4 years 11 months 26 days

^[1]

Aggregate intrinsic value, exercisable | $

^[1]

[1]	Warrants issued, outstanding, and exercisable exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.
[2]	represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

Schedule of Stock Options Activity (Details)	3 Months Ended
Schedule of Stock Options Activity (Details)	Mar. 31, 2025 USD ($) $ / shares shares
Equity [Abstract]
Number of options, outstanding beginning balance \| shares	9,612
Weighted average exercise price, beginning balance \| $ / shares	$ 2,248.58
Number of options, granted \| shares
Weighted average exercise price, granted \| $ / shares
Number of options, exercised \| shares
Weighted average exercise price, exercised \| $ / shares
Number of options, forfeited \| shares	(9)
Weighted average exercise price, forfeited \| $ / shares	$ 1,760.50
Number of options, outstanding ending balance \| shares	9,603
Weighted average exercise price, ending balance \| $ / shares	$ 2,249.04
Weighted average remaining life in years, outstanding	6 years
Aggregate intrinsic value, ending balance \| $
Number of options, exercisable ending balance \| shares	7,013
Weighted average exercise price, Exercisable \| $ / shares	$ 3,014.29
Weighted average remaining life in years, exercisable	5 years 3 months 18 days
Aggregate intrinsic value, exercisable \| $

Cover - $ / shares	3 Months Ended
Cover - $ / shares	Mar. 31, 2025	May 07, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2025
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,773,456
Entity Listing, Par Value Per Share	$ 0.0001

Schedule of Information Related to Stock Warrants (Details) - $ / shares

3 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of warrants, outstanding

3,852,258

^[1]

1,747,093

Options exercisable, Number of options

^[1]

1,746,793

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of warrants, outstanding

3,852,258

Warrant exercisable, weighted average remaining life in years

4 years 11 months 26 days

Options exercisable, Number of options

1,746,793

Exercise Price One [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 1.00

Number of warrants, outstanding

3,062,465

Warrant exercisable, weighted average remaining life in years

5 years 2 months 8 days

Options exercisable, Number of options

957,200

Exercise Price Two [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 2.06

Number of warrants, outstanding

679,800

Warrant exercisable, weighted average remaining life in years

5 years 2 months 8 days

Options exercisable, Number of options

679,800

Exercise Price Three [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 12.50

Number of warrants, outstanding

7,000

Warrant exercisable, weighted average remaining life in years

2 years 2 months 19 days

Options exercisable, Number of options

7,000

Exercise Price Four [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 47.50

Number of warrants, outstanding

20,347

Warrant exercisable, weighted average remaining life in years

3 years 11 months 12 days

Options exercisable, Number of options

20,347

Exercise Price Five [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 57.75

Number of warrants, outstanding

19,965

Warrant exercisable, weighted average remaining life in years

3 years 3 months 7 days

Options exercisable, Number of options

19,965

Exercise Price Six [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 350.00

Number of warrants, outstanding

27,551

Warrant exercisable, weighted average remaining life in years

3 years 29 days

Options exercisable, Number of options

27,551

Exercise Price Seven [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 700.00

Number of warrants, outstanding

13,944

Warrant exercisable, weighted average remaining life in years

2 years 8 months 12 days

Options exercisable, Number of options

13,944

Exercise Price Eight [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 1,760.50

Number of warrants, outstanding

200

Exercise Price Nine [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 2,415.00

Number of warrants, outstanding

3,651

Warrant exercisable, weighted average remaining life in years

2 years 8 months 12 days

Options exercisable, Number of options

3,651

Exercise Price Ten [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted average exercise price, outstanding

$ 4,025.00

Number of warrants, outstanding

17,335

Warrant exercisable, weighted average remaining life in years

2 years 8 months 12 days

Options exercisable, Number of options

17,335

[1]	Warrants issued, outstanding, and exercisable exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2025
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Income Taxes (Details Narrative)	3 Months Ended
Income Taxes (Details Narrative)	Mar. 31, 2025	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%	0.00%

Summary of Warrant Activity (Details) (Parenthetical)	3 Months Ended
Summary of Warrant Activity (Details) (Parenthetical)	Mar. 31, 2025 $ / shares shares
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	9,603
Number of warrants, exercised
March 2025 PreFunded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	2,105,265
Warrants exercise price \| $ / shares	$ 0.0001
November 2024 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, exercised	957,200
November 2024 Warrants [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share \| $ / shares	$ 2.06
November 2024 Warrants [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share \| $ / shares	$ 1.00

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Apr. 07, 2025 $ / shares shares
Pre Funded Warrants [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Exercise price per share \| $ / shares	$ 0.0001
Private Placement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Warrant purchase	2,105,265
Private Placement [Member] \| Pre Funded Warrants [Member]
Subsequent Event [Line Items]
Pre-funded warrants exercised	2,105,265

Commitments and Contingencies (Details Narrative)									3 Months Ended
Commitments and Contingencies (Details Narrative)	Jan. 09, 2025 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jan. 30, 2024 USD ($)	Jan. 15, 2024 USD ($)	Mar. 29, 2023 USD ($) shares	Feb. 28, 2023 USD ($)	Jan. 18, 2019 USD ($) ft²	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Invoices from a vendor		$ 162,800	$ 992,176
Accrued interest									$ 2,398,964		$ 1,894,041
Number of operating lease square feet \| ft²								3,500
Lease cost								$ 89,000
Operating lease rent expense								$ 497,000	44,196	$ 22,047
Lease Commitment [Member]
Loss Contingencies [Line Items]
Operating lease rent expense	$ 120,819				$ 112,064
License Agreement [Member] \| L&F Research LLC [Member]
Loss Contingencies [Line Items]
Milestone payment description							the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”)
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver A [Member]
Loss Contingencies [Line Items]
Debt forgiveness							$ 351,579
Cash payment						$ 648,421	$ 648,421
Maturity date							Mar. 31, 2023
Reclassifications of temporary to permanent equity shares \| shares						188
Reclassifications of temporary to permanent equity						$ 331,331
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver B [Member]
Loss Contingencies [Line Items]
Cash payment				$ 500,000			$ 500,000
Maturity date							Jan. 31, 2024
Net proceeds from issuance of equity capital							$ 30,000,000
Accrued Expenses and Other Current Liabilities [Member]
Loss Contingencies [Line Items]
Accrued interest									388,450
Interest claim									$ 941,074

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2025	Dec. 31, 2024
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	2,568,198	2,508,198
Common stock, shares outstanding	2,568,191	2,508,191
Treasury stock, shares	7	7
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	50
Preferred stock, shares outstanding	50	50
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

Since the date the Company’s December 31, 2024 financial statements were issued in its 2024 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table presents the computation of basic and diluted net loss per common share:


	For the Three Months Ended
	March 31,
	2025			2024
Numerator:
Net loss attributable to common stockholders	$	(2,256,930	)	$	(2,826,737	)

Denominator (weighted average quantities):
Common shares outstanding		2,545,524			623,600
Add: Prefunded warrants		561,404			-
Denominator for basic and diluted net loss per share		3,106,928			623,600

Basic and Diluted Net Loss per Common Share	$	(0.73	)	$	(4.53	)

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Three Months Ended
	March 31,
	2025		2024
Warrants ^[1] 1		3,852,258		689,520
Options		9,603		10,243
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		3,864,000		701,902

Segment Reporting

The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the condensed consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total assets. The Company has not yet generated any revenue from product sales.

Vendor Concentration

As of March 31, 2025 and December 31, 2024, accounts payable to one vendor accounted for 55% and 56%, respectively, related to research and development. The Company relies on this vendor to perform critical research and development.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this standard but does not expect it to have a material impact on its financial statements.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity. The amendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required to disclose and qualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of selling expenses and the definition of selling expenses. The amendments in this update should be applied prospectively to financial statements issued for reporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted, the new guidance becomes effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows.

Business Organization, Nature of Operations and Basis of Presentation (Details Narrative)	Dec. 04, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)

Preferred Stock [Member]

Series A Preferred Stock [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Treasury Stock, Common [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance - December 31, 2023 at Dec. 31, 2023

$ 1

$ 40

$ (7,168)

$ 114,300,849

$ (103,219,124)

$ 11,074,598

Balance, shares at Dec. 31, 2023

5,062

405,212

Balance, shares at Dec. 31, 2023

(7)

Issuance of common stock pursuant to vendor agreements

$ 1

79,199

79,200

Issuance of common stock pursuant to vendor agreements, shares

9,000

Stock-based compensation

223,573

Net loss

(2,826,737)

Exercise of warrants

$ 21

2,672,479

2,672,500

Exercise of warrants, shares

213,800

Exercise of pre-funded warrants

$ 13

(13)

Exercise of pre-funded warrants, shares

131,481

Round up share adjustment due to reverse split

$ 8

(8)

Round up share adjustment due to reverse split, shares

75,410

Balance - March 31, 2024 at Mar. 31, 2024

$ 1

$ 83

$ (7,168)

117,276,079

(106,045,861)

11,223,134

Balance, shares at Mar. 31, 2024

5,062

834,903

Balance, shares at Mar. 31, 2024

(7)

Balance - December 31, 2023 at Dec. 31, 2024

$ 1

$ 251

$ (7,168)

121,155,922

(112,632,559)

$ 8,516,447

Balance, shares at Dec. 31, 2024

5,062

2,508,198

Balance, shares at Dec. 31, 2024

(7)

Issuance of common stock pursuant to vendor agreements

$ 6

81,594

$ 81,600

Issuance of common stock pursuant to vendor agreements, shares

60,000

Private placement of warrants

^[1]

1,663,052

Warrant modification

53,890

Stock-based compensation

72,291

Net loss

(2,256,930)

Balance - March 31, 2024 at Mar. 31, 2025

$ 1

$ 257

$ (7,168)

$ 123,026,749

$ (114,889,489)

$ 8,130,350

Balance, shares at Mar. 31, 2025

5,062

2,568,198

Balance, shares at Mar. 31, 2025

(7)

[1]	Includes gross proceeds of $1,999,791 less cash issuance costs of $282,849 and a non-cash warrant modification charge of $53,890

Schedule of Computation of Basic and Diluted Loss Per Common Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Accounting Policies [Abstract]
Net loss attributable to common stockholders	$ (2,256,930)	$ (2,826,737)
Common shares outstanding	2,545,524	623,600
Add: Prefunded warrants	561,404
Denominator for basic	3,106,928	623,600
Denominator for diluted	3,106,928	623,600
Basic Net Loss per Common Share	$ (0.73)	$ (4.53)
Diluted Net Loss per Common Share	$ (0.73)	$ (4.53)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Business Organization, Nature of Operations and Basis of Presentation

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Organization, Nature of Operations and Basis of Presentation

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

Organization and Operations

ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2025 and for the three months ended March 31, 2025 and 2024. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025.

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented.

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Accounts Payable [Member] \| Customer Concentration Risk [Member] \| One Vendor Accounted [Member]
Product Information [Line Items]
Concentration risk percentage	55.00%	56.00%

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

3 Months Ended

Mar. 31, 2025

Mar. 31, 2024

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

3,864,000

701,902

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

3,852,258

689,520

Share-Based Payment Arrangement, Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

9,603

10,243

Series A Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

Series B Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

2,067

[1]

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2025

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 4 – Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of March 31, 2025 and December 31, 2024:

	March 31,		December 31,
	2025		2024

Payroll accrual	$	1,101,584	$	1,039,338
Bonus accrual		726,938		536,500
Interest accrual		388,450		268,972
Other accrued expenses		111,831		41,970
Accrued issuable equity		62,900		-
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,398,964	$	1,894,041

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2025 USD ($)
Statement of Stockholders' Equity [Abstract]
Gross proceeds	$ 1,999,791
Issuance costs	282,849
Non cash warrant costs	$ 53,890

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Use of Estimates

Net Loss Per Common Share


	For the Three Months Ended
	March 31,
	2025			2024
Numerator:
Net loss attributable to common stockholders	$	(2,256,930	)	$	(2,826,737	)

Denominator (weighted average quantities):
Common shares outstanding		2,545,524			623,600
Add: Prefunded warrants		561,404			-
Denominator for basic and diluted net loss per share		3,106,928			623,600

Basic and Diluted Net Loss per Common Share	$	(0.73	)	$	(4.53	)

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Three Months Ended
	March 31,
	2025		2024
Warrants ^[1] 1		3,852,258		689,520
Options		9,603		10,243
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		3,864,000		701,902

Segment Reporting

Vendor Concentration

Recently Issued Accounting Pronouncements

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

+ Details

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2025	Dec. 31, 2024
Current Assets:
Cash	$ 1,611,532	$ 1,530,924
Prepaid expenses and other current assets	498,778	184,873
Total Current Assets	2,110,310	1,715,797
In-process research and development	18,647,903	18,647,903
Vendor deposit	178,476	178,476
Deferred offering costs	48,852	57,238
Total Assets	20,985,541	20,599,414
Current Liabilities:
Accounts payable	9,604,568	9,337,267
Accrued expenses and other current liabilities	2,398,964	1,894,041
Total Current Liabilities	12,003,532	11,231,308
Deferred tax liability	851,659	851,659
Total Liabilities	12,855,191	12,082,967
Commitments and contingencies (Note 6)
Stockholders’ Equity:
Common stock	257	251
Additional paid-in-capital	123,026,749	121,155,922
Accumulated deficit	(114,889,489)	(112,632,559)
Treasury stock, at cost, 7 shares at March 31, 2025 and December 31, 2024,	(7,168)	(7,168)
Total Stockholders’ Equity	8,130,350	8,516,447
Total Liabilities and Stockholders’ Equity	20,985,541	20,599,414
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock
Series B Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	$ 1	$ 1

Schedule of Information Related to Stock Options (Details)	3 Months Ended
	Mar. 31, 2025 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number of options	9,603
Options exercisable, weighted average remaining life in years	5 years 3 months 18 days
Options exercisable, Number of options	7,013
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 152.50
Options outstanding, Number of options	4,157
Options exercisable, weighted average remaining life in years	8 years 1 month 6 days
Options exercisable, Number of options	1,674
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 738.50
Options outstanding, Number of options	286
Options exercisable, weighted average remaining life in years	7 years 9 months 18 days
Options exercisable, Number of options	191
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 791.00
Options outstanding, Number of options	38
Options exercisable, weighted average remaining life in years	7 years 10 months 24 days
Options exercisable, Number of options	26
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 1,760.50
Options outstanding, Number of options	1,270
Options exercisable, weighted average remaining life in years	1 year 8 months 12 days
Options exercisable, Number of options	1,270
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 3,965.50
Options outstanding, Number of options	37
Options exercisable, weighted average remaining life in years	7 years 2 months 12 days
Options exercisable, Number of options	37
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 4,053.00
Options outstanding, Number of options	2,095
Options exercisable, weighted average remaining life in years	4 years
Options exercisable, Number of options	2,095
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price \| $ / shares	$ 5,726.00
Options outstanding, Number of options	1,720
Options exercisable, weighted average remaining life in years	6 years 2 months 12 days
Options exercisable, Number of options	1,720

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash Flows From Operating Activities:
Net loss	$ (2,256,930)	$ (2,826,737)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	72,291	223,573
Issuance of common stock pursuant to vendor agreements	81,600	79,200
Depreciation of fixed assets		2,600
Non-cash rent expense		7,839
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(313,905)	(651,017)
Accounts payable	191,445	(303,837)
Deferred offering costs	8,386
Operating lease liability		(8,656)
Accrued expenses and other current liabilities	445,061	(299,563)
Net Cash Used In Operating Activities	(1,772,052)	(3,776,598)
Cash Flows From Financing Activities:
Exercise of warrants		2,672,500
Private placement of warrants	1,999,791
Registration and issuance costs associated with warrant issuance	(147,131)
Net Cash Provided By Financing Activities	1,852,660	2,672,500
Net Increase / (Decrease) in Cash	80,608	(1,104,098)
Cash - Beginning of Period	1,530,924	3,137,674
Cash - End of Period	1,611,532	2,033,576
Supplemental Disclosures of Cash Flow Information:
Warrant modification - incremental value	53,890
Accounts payable and accrued expenses for private placement costs	$ 135,718

Stockholders’ Equity (Details Narrative) - USD ($)				3 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Apr. 11, 2025	Mar. 20, 2025	Mar. 07, 2025	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Nov. 05, 2024	Nov. 04, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity				$ 62,900
Stock based compensation expense				72,291	$ 223,573
Unrecognized stock-based compensation expense				$ 249,602
Weighted average period				1 year 1 month 6 days
Gross proceeds				$ 1,999,791
Issuance costs				147,131
Other costs				$ 282,849
March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price				$ 0.0001
Research and Development Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense				$ 15,447	15,447
General and Administrative Expense [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense				$ 56,844	$ 208,126
Subsequent Event [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
stock issued during ther period , shares	100,000
Marketing Agreements [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
stock issued during ther period , shares		100,000
prepaid expense		$ 70,100
Number of common stock for future issuance				100,000
Equity				$ 62,900
Private Placement [Member] \| March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants sold			2,105,265
Warrants exercise price			$ 0.0001
Issuance costs			$ 282,849
Placement fees			199,863
Legal fee			56,844
Other costs			$ 26,142
Private Placement [Member] \| March 2025 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants sold			2,105,265
Warrants exercise price			$ 1.00
Private Placement [Member] \| March 2025 Common Warrants And Prefunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants sold							957,200
Warrants exercise price			$ 0.9499				$ 1.00	$ 2.06
Gross proceeds			$ 2,000,000.0
Issuance costs			$ 53,890

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Payroll accrual	$ 1,101,584	$ 1,039,338
Bonus accrual	726,938	536,500
Interest accrual	388,450	268,972
Other accrued expenses	111,831	41,970
Accrued issuable equity	62,900
Registration delay liability	7,261	7,261
Total accrued expenses and other current liabilities	$ 2,398,964	$ 1,894,041

- Definition

Amount of liabilities classified as other.

+ References + Details

Subsequent Events

3 Months Ended

Mar. 31, 2025

Subsequent Events [Abstract]

Subsequent Events

Note 8 – Subsequent Events

The Company has evaluated subsequent events through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as discussed below.

Stock Warrants

Subsequent to March 31, 2025, the Private Placement investor exercised 2,105,265 pre-funded warrants to purchase 2,105,265 shares of common stock at an exercise price of $0.0001 per share.

Stockholders’ Equity

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Stockholders’ Equity

Note 7 – Stockholders’ Equity

Common Stock

On March 20, 2025, the Company entered into a marketing agreement with a vendor in which the Company issued 100,000 shares of common stock and cash in exchange for digital marketing services. The fair value of the common stock was established as a prepaid expense and the Company is recognizing $70,100 of the expense over the three-month term of the contract. As of March 31, 2025, the Company had not yet issued the 100,000 shares of common stock and therefore classified the fair value of the common stock as accrued issuable equity within accrued expenses and other current liabilities on the condensed consolidated balance sheet using the market value of $62,900 on March 31, 2025.

On April 11, 2025, the Company issued the 100,000 shares of common stock to the vendor.

Stock-Based Compensation

For the three months ended March 31, 2025 the Company recorded stock-based compensation expense of $72,291 (of which, $15,447 was included in research and development and $56,844 was included in general and administrative expense) related to options issued to employees and consultants. For the three months ended March 31, 2024 the Company recorded stock-based compensation expense of $223,573 (of which, $15,447 was included in research and development and $208,126 was included in general and administrative expense) related to options issued to employees and consultants. As of March 31, 2025 there was $249,602 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.1 years.

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

Stock Options

A summary of the option activity for the three months ended March 31, 2025 is presented below:

Schedule of Stock Options Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		-			-
Exercised		-			-
Expired		(9	)		1,760.50
Outstanding, March 31, 2025		9,603		$	2,249.04		6.0	$	-

Exercisable, March 31, 2025		7,013		$	3,014.29		5.3	$	-

The following table presents information related to stock options as of March 31, 2025:

	Options Outstanding		Options Exercisable
			Weighted
		Outstanding	Average	Exercisable
	Exercise	Number of	Remaining Life	Number of
	Price	Options	In Years	Options
$	152.50	4,157	8.1	1,674
$	738.50	286	7.8	191
$	791.00	38	7.9	26
$	1,760.50	1,270	1.7	1,270
$	3,965.50	37	7.2	37
$	4,053.00	2,095	4.0	2,095
$	5,726.00	1,720	6.2	1,720
		9,603	5.3	7,013

Stock Warrants

On March 7, 2025, the Company closed on a private placement (the “Private Placement”) with an institutional investor, pursuant to which the Company sold pre-funded warrants (the “March 2025 Pre-Funded Warrants”) to purchase 2,105,265 shares of common stock and Series A-3 common warrants (the “March 2025 Common Warrants”) to purchase 2,105,265 shares of common stock at a combined purchase price of $0.9499 which resulted in gross proceeds of approximately $2.0 million. In addition, the Company and the investor entered into an amendment to certain November 5, 2024 common share purchase warrants to reduce the exercise price of certain outstanding warrants to purchase 957,200 shares of common stock from $2.06 per share to $1.00 per share. The $53,890 incremental fair value of the modified warrants as compared to the original warrants was recognized as an additional issuance cost of the Private Placement. The March 2025 Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all March 2025 Pre-Funded Warrants are exercised in full, and have an exercise price of $0.0001 per share. The March 2025 Common Warrants are exercisable upon Stockholder Approval for a term of five years following stockholder approval and have an exercise price of $1.00 per share. Total cash issuance costs were $282,849 including $199,863 of placement fees, $56,844 of legal fees, and $26,142 of other costs.

The modification date fair value of warrants modified during the three months ended March 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

	For the Three Months Ended
	March 31,
	2025			2024
Fair value of common stock on date of grant	$	0.98			n/a
Risk free interest rate		4.09	%		n/a
Expected term (years)		5.3 years			n/a
Expected volatility		125	%		n/a
Expected dividends		0.00	%		n/a

ZYVERSA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

A summary of the warrant activity for the three months ended March 31, 2025, is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued^[1]		2,105,265			1.00
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Forfeited		-			-
Exercised		-			-
Outstanding, March 31, 2025^[1]		3,852,258		$	27.26		5.06	$	-

Exercisable, March 31, 2025^[1]		1,746,793		$	58.71		4.99	$	-

[1]	Warrants issued, outstanding, and exercisable exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

The following table presents information related to stock warrants as of March 31, 2025:

	Warrants Outstanding		Warrants Exercisable
		Outstanding	Weighted Average	Exercisable
	Exercise	Number of	Remaining Life	Number of
	Price	Warrants	In Years	Warrants
$	1.00	3,062,465	5.19	957,200
$	2.06	679,800	5.19	679,800
$	12.50	7,000	2.22	7,000
$	47.50	20,347	3.95	20,347
$	57.75	19,965	3.27	19,965
$	350.00	27,551	3.08	27,551
$	700.00	13,944	2.70	13,944
$	1,760.50	200	-	-
$	2,415.00	3,651	2.70	3,651
$	4,025.00	17,335	2.70	17,335
		3,852,258	4.99	1,746,793

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating Expenses:
Research and development	$ 258,876	$ 512,937
General and administrative	1,885,695	2,313,699
Total Operating Expenses	2,144,571	2,826,636
Loss From Operations	(2,144,571)	(2,826,636)
Other (Income) Expense:
Interest (income) expense	119,559	101
Change in fair value of equity payable	(7,200)
Net Loss	$ (2,256,930)	$ (2,826,737)
Net Loss Per Share
Basic	$ (0.73)	$ (4.53)
Diluted	$ (0.73)	$ (4.53)
Weighted Average Number of Common Shares Outstanding
Basic	3,106,928	623,600
Diluted	3,106,928	623,600

Pay vs Performance Disclosure - USD ($)	3 Months Ended
Pay vs Performance Disclosure - USD ($)	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,256,930)	$ (2,826,737)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Going Concern and Management’s Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,611,532		$ 1,530,924
Working capital deficit	9,900,000
Net loss	2,256,930	$ 2,826,737
Net cash used In operating activities	(1,772,052)	$ (3,776,598)
Accumulated deficit	$ 114,889,489		$ 112,632,559

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Income Taxes

3 Months Ended

Mar. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 5 – Income Taxes

The tax provisions for the three months ended March 31, 2025 and 2024 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was 0.00% and 0.00% for the three months ended March 31, 2025 and 2024, because the Company has significant net deferred tax assets, including those associated with net operating losses, that are subject to a full valuation allowance

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2025

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Stock Options Activity

A summary of the option activity for the three months ended March 31, 2025 is presented below:

Schedule of Stock Options Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		-			-
Exercised		-			-
Expired		(9	)		1,760.50
Outstanding, March 31, 2025		9,603		$	2,249.04		6.0	$	-

Exercisable, March 31, 2025		7,013		$	3,014.29		5.3	$	-

Schedule of Information Related to Stock Options

The following table presents information related to stock options as of March 31, 2025:

	Options Outstanding		Options Exercisable
			Weighted
		Outstanding	Average	Exercisable
	Exercise	Number of	Remaining Life	Number of
	Price	Options	In Years	Options
$	152.50	4,157	8.1	1,674
$	738.50	286	7.8	191
$	791.00	38	7.9	26
$	1,760.50	1,270	1.7	1,270
$	3,965.50	37	7.2	37
$	4,053.00	2,095	4.0	2,095
$	5,726.00	1,720	6.2	1,720
		9,603	5.3	7,013

Summary of Warrant Activity

A summary of the warrant activity for the three months ended March 31, 2025, is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued^[1]		2,105,265			1.00
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Forfeited		-			-
Exercised		-			-
Outstanding, March 31, 2025^[1]		3,852,258		$	27.26		5.06	$	-

Exercisable, March 31, 2025^[1]		1,746,793		$	58.71		4.99	$	-

[1]	Warrants issued, outstanding, and exercisable exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.

[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.

Schedule of Information Related to Stock Warrants

The following table presents information related to stock warrants as of March 31, 2025:

	Warrants Outstanding		Warrants Exercisable
		Outstanding	Weighted Average	Exercisable
	Exercise	Number of	Remaining Life	Number of
	Price	Warrants	In Years	Warrants
$	1.00	3,062,465	5.19	957,200
$	2.06	679,800	5.19	679,800
$	12.50	7,000	2.22	7,000
$	47.50	20,347	3.95	20,347
$	57.75	19,965	3.27	19,965
$	350.00	27,551	3.08	27,551
$	700.00	13,944	2.70	13,944
$	1,760.50	200	-	-
$	2,415.00	3,651	2.70	3,651
$	4,025.00	17,335	2.70	17,335
		3,852,258	4.99	1,746,793

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Issuance Date Fair Value of Stock Warrants

The modification date fair value of warrants modified during the three months ended March 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

	For the Three Months Ended
	March 31,
	2025			2024
Fair value of common stock on date of grant	$	0.98			n/a
Risk free interest rate		4.09	%		n/a
Expected term (years)		5.3 years			n/a
Expected volatility		125	%		n/a
Expected dividends		0.00	%		n/a

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details